Buy Symbiotec Pharmalab; target of Rs 1800: Motilal Oswal

Moneycontrol • 2 days ago

Original source

Key Investment Pillars

  • Strong base business in API segment with 16% YoY growth in revenue, driven by healthy demand and favorable product mix.
  • Milestone achievements in injectable segment, including ANDA filing and long-term CDMO contracts with US and EU-based alternate protein companies.
  • Expanding product portfolio and increasing traction in existing products, with a focus on classical fermentation APIs and synthetic biology partnerships.
  • CDMO segment expected to drive long-term growth, with take-or-pay contracts and capacity expansion.

Thesis Validation Checklist

  • Watch for continued growth in API segment revenue and profitability.
  • Monitor progress on ANDA filings and CDMO contract execution.
  • Track expansion of product portfolio and increasing traction in existing products.
  • Evaluate the company's ability to maintain its competitive position in the API and CDMO markets.